Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction

SAN DIEGO, June 24, 2020 (GLOBE NEWSWIRE) -Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of a literature review article by Biology of Reproduction that identifies and reviews 10 postcoital test (PCT) studies of vaginal contraceptives involving 9 test products, including Daré’s investigational hormone-free, monthly contraceptive Ovaprene, currently under a license agreement with Bayer for commercialization in the U.S.